Elevated levels of intestinal inflammation in Clostridium difficile infection associated with fluoroquinolone-resistant C. difficile.
Pawlowski
S W
SW
Archbald-Pannone
L
L
Carman
R J
RJ
Alcantara-Warren
C
C
Lyerly
D
D
Genheimer
C W
CW
Gerding
D N
DN
Guerrant
R L
RL
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001372:Aza Compounds / Q000494:pharmacology*; D016360:Clostridioides difficile / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D003015:Clostridium Infections / Q000382:microbiology / Q000503:physiopathology; D024881:Drug Resistance, Bacterial; D005243:Feces / Q000737:chemistry* / Q000382:microbiology; D024841:Fluoroquinolones / Q000494:pharmacology*; D006801:Humans; D007249:Inflammation / Q000503:physiopathology; D007422:Intestines / Q000276:immunology / Q000382:microbiology / Q000503:physiopathology; D007781:Lactoferrin / Q000032:analysis / Q000378:metabolism*; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D011804:Quinolines / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D007781:Lactoferrin; D000077266:Moxifloxacin